|

Autologous Anti-CD19 CAR-expressing T-lymphocytes IC19/1563 Clinical Trials

1 actively recruiting trial across 1 location

Also known as: Autologous CAR-T Cells IC19/1563, CD19-directed CAR-T Cells IC19/1563, IC19 1563, IC19-1563, IC19/1563

Pipeline

Phase 1: 1

Top Sponsors

  • Mayo Clinic1

Indications

  • Refractory Small Lymphocytic Lymphoma1
  • Refractory Chronic Lymphocytic Leukemia1
  • Recurrent Small Lymphocytic Lymphoma1
  • Recurrent Chronic Lymphocytic Leukemia1
  • Refractory B-Cell Non-Hodgkin Lymphoma1

Rochester, Minnesota1 trial

CD19-Directed CAR-T Cell Therapy for the Treatment of Relapsed/Refractory B Cell Malignancies

Mayo Clinic in Rochester

Phase 1

Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.

This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.